×
OpGen EBITDA 2014-2024 | OPGN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
OpGen ebitda from 2014 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
OpGen EBITDA 2014-2024 | OPGN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
OpGen ebitda from 2014 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
Danaher (DHR)
$136B
CVS Health (CVS)
$78.4B
Elevance Health (ELV)
$62.6B
Cencora (COR)
$56.8B
DiDi Global (DIDIY)
$26.9B
Labcorp Holdings (LH)
$20.4B
Natera (NTRA)
$19B
BioMerieux (BMXMF)
$16.9B
EUROFINS SCIENT (ERFSF)
$14B
CochLear (CHEOY)
$13.1B
Solventum (SOLV)
$12.7B
ICON (ICLR)
$11.6B
Revvity (RVTY)
$11B
Viatris (VTRS)
$10.4B
Avantor (AVTR)
$9.1B
Medpace Holdings (MEDP)
$9B
Sonic Healthcare (SKHHY)
$8.9B
HealthEquity (HQY)
$8.4B
Caris Life Sciences,�Inc (CAI)
$7.7B
Charles River Laboratories (CRL)
$7.6B
Amplifon S.p.A (AMFPF)
$5.4B
Bausch + Lomb (BLCO)
$4.9B
BrightSpring Health Services (BTSG)
$3.5B
Sotera Health (SHC)
$3.1B
Surgery Partners (SGRY)
$2.9B
Concentras Parent (CON)
$2.5B
Organon (OGN)
$2.5B
Alignment Healthcare (ALHC)
$2.5B
GeneDx Holdings (WGS)
$2.2B
Progyny (PGNY)
$1.9B